EUVIMEDEUVIMED entdecken
Crossref

Characterizing and Targeting of BCL ‐2 Family Members in Nasopharyngeal Carcinoma

A A Thai iD, R J Young, M Bressel, G L Kelly, N Sejic, S W Tsao, A Trigos, D Rischin, B J Solomon

Head & Neck · 2025

DOI: 10.1002/hed.27973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2025. Verfasst von A A Thai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Proto-Oncogene Proteins c-bcl-2, Nasopharyngeal Neoplasms, Antineoplastic Agents. Die Arbeit nennt 74 Literaturangaben. Gefördert von: Research Grant Council, Hong Kong, NSFC/RGC, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The success of BH3 mimetics in hematological malignancies has spurred interest in their application in solid tumors. We examined the expression of the BCL‐2 family of molecules in NPC tumors and cell lines and explored the anticancer efficacy of BH3 mimetics in vitro.

Methods

Immunohistochemistry for BCL‐2, MCL‐1, BCL‐xL, and transcriptomic analyses was conducted on NPC tumors. The efficacy of ABT‐199, S63845, and ABT‐737 were examined as monotherapy and in combination with cisplatin in NPC cell lines. RNA sequencing was performed to identify up and downregulated pathways in sensitive cell lines.

Results

One hundred and forty‐nine EBV‐positive NPC and 15 EBV‐negative NPC were identified. Expression of BCL‐2 was more frequent in EBV‐positive NPC. BCL‐2, MCL‐1, and BCL‐xL expression was not prognostic for overall survival. Marked sensitivity was seen with the combination of S63845 and cisplatin in NPC43.

Conclusion

Our study demonstrates the therapeutic potential of combining cisplatin and S63845, which warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaProto-Oncogene Proteins c-bcl-2Nasopharyngeal NeoplasmsAntineoplastic AgentsHumansSulfonamidesCisplatinCell Line, TumorBiphenyl CompoundsBridged Bicyclo Compounds, HeterocyclicNitrophenolsPiperazinesFemalebcl-X ProteinMaleMiddle AgedImmunohistochemistryMyeloid Cell Leukemia Sequence 1 ProteinPyrimidinesThiophenes

Stichwörter der Autor:innen

BCL2BCLxlMCL1NPCapoptosis

Substanzen

SulfonamidesCisplatinProto-Oncogene Proteins c-bcl-2Biphenyl CompoundsBridged Bicyclo Compounds, HeterocyclicABT-737NitrophenolsPiperazinesbcl-X ProteinS63845

Autor:innen und Institutionen

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia.
  • Department of Medical Biology, The University of Melbourne, Melbourne, Australia.

ORCID-Profile: A A Thai

Förderung

  • Research Grant Council, Hong Kong
  • NSFC/RGC
  • National Natural Science Foundation of China

Zitieren

APA

Thai, A. A., Young, R. J., Bressel, M., Kelly, G. L., Sejic, N., Tsao, S. W., Trigos, A., Rischin, D., & Solomon, B. J. (2025). Characterizing and Targeting of BCL ‐2 Family Members in Nasopharyngeal Carcinoma. Head & Neck. https://doi.org/10.1002/hed.27973

Vancouver

Thai AA, Young RJ, Bressel M, Kelly GL, Sejic N, Tsao SW, et al. Characterizing and Targeting of BCL ‐2 Family Members in Nasopharyngeal Carcinoma. Head & Neck. 2025. doi:10.1002/hed.27973

BibTeX
@article{Thai2025,
  author = {Thai, A A and Young, R J and Bressel, M and Kelly, G L and Sejic, N and Tsao, S W and Trigos, A and Rischin, D and Solomon, B J},
  title = {Characterizing and Targeting of BCL ‐2 Family Members in Nasopharyngeal Carcinoma},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.27973}
}
Kostenlos starten →